Clinical Trials Browser

Phase 3 × Completed × avelumab × Clear all

NCT02926196 2025-12-12

A-Brave

Phase 3 Completed

Triple Negative Breast Neoplasms

NCT02684006 2025-07-30

JAVELIN Renal 101

Phase 3 Completed

886 enrolled 37 charts 1 FDA

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT02576574 2025-01-31

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Phase 3 Completed

1,214 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT02603432 2024-03-27

JAVELIN Bladder 100

Phase 3 Completed

700 enrolled 35 charts 1 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT02580058 2023-07-10

JAVELIN Ovarian 200

Phase 3 Completed

566 enrolled 40 charts

Ovarian Neoplasms

NCT02625610 2022-06-09

Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)

Phase 3 Completed

499 enrolled 22 charts

Neoplasm Metastasis, Neoplasms

NCT02625623 2020-11-24

Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)

Phase 3 Completed

371 enrolled 18 charts

Gastrointestinal

Recurrence, Stomach Neoplasms

NCT02395172 2020-08-03

Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)

Phase 3 Completed

792 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung